Inhibition of cow’s milk allergy development in mice by oral delivery of β-lactoglobulin-derived peptides loaded PLGA nanoparticles is associated with systemic whey-specific immune silencing,Clinical & Experimental Allergy

当前位置： X-MOL 学术 › Clin. Exp. Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Inhibition of cow’s milk allergy development in mice by oral delivery of β-lactoglobulin-derived peptides loaded PLGA nanoparticles is associated with systemic whey-specific immune silencing
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2021-06-17 , DOI: 10.1111/cea.13967
Mengshan Liu _{1,

2} , Suzan Thijssen ₂ , Cornelus F van Nostrum ₁ , Wim E Hennink ₁ , Johan Garssen _{2,

3} , Linette E M Willemsen ₂

Affiliation

Two to four percentage of infants are affected by cow's milk allergy (CMA), which persists in 20% of cases. Intervention approaches using early oral exposure to cow's milk protein or hydrolysed cow's milk formula are being studied for CMA prevention. Yet, concerns regarding safety and/or efficacy remain to be tackled in particular for high-risk non-exclusively breastfed infants. Therefore, safe and effective strategies to improve early life oral tolerance induction may be considered.

中文翻译：

通过口服递送载有 β-乳球蛋白衍生肽的 PLGA 纳米颗粒抑制小鼠牛奶过敏的发展与全身乳清特异性免疫沉默有关

2% 到 4% 的婴儿受到牛奶过敏 (CMA) 的影响，这种情况在 20% 的病例中持续存在。正在研究使用早期口服接触牛奶蛋白或水解牛奶配方的干预方法来预防 CMA。然而，关于安全性和/或有效性的问题仍有待解决，特别是对于高风险的非纯母乳喂养婴儿。因此，可以考虑采用安全有效的策略来改善生命早期口服耐受诱导。

更新日期：2021-06-17

点击分享查看原文

点击收藏

阅读更多本刊最新论文